|
1.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 -  10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
2.
|
|
19 p, 837.6 KB |
Malignant bone tumors (other than Ewing's) : clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
/
Redondo, Andrés (Hospital Universitario La Paz (Madrid)) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Ortiz-Cruz, Eduardo (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez-Martin, Jose A. (Hospital 12 de Octubre (Madrid)) ;
Correa, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cruz, Josefina (Hospital Universitario de Canarias (La Laguna)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Santos, Aurelio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García del Muro, Xavier (Institut Catalá d'Oncologia Hospitalet) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. [...]
2017 - 10.1007/s00280-017-3436-0
Cancer Chemotherapy and Pharmacology, Vol. 80 Núm. 6 (january 2017) , p. 1113-1131
|
|
|
3.
|
|
12 p, 682.4 KB |
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
/
Hidalgo-Ríos, Samuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Carrillo García, Jaime (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Moura, David S. (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Redondo, Andrés (Hospital Universitario La Paz. Servicio de Oncología Médica. Instituto de Investigación en Salud (IdiPAZ)) ;
Italiano, Antoine (Institut Bergonié. Department of Oncology) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Hindi, Nadia (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica) ;
López-Guerrero, J.A (Laboratory of Molecular Biology. Fundación Instituto Valenciano de Oncología) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz. Sección de Radiología musculoesquelética) ;
Le Cesne, Axel (Gustave Roussy Cancer Campus. Department of Medical Oncology) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori. Adult Mesenchymal and Rare Tumor Unit. Department of Cancer Medicine) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Léon Bérard. Université Claude Bernard Lyon) ;
Cruz-Jurado, Josefina (Hospital Universitario de Canarias. Servicio de Oncología Médica) ;
Martín-Broto, Javier (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica)
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. [...]
2022 - 10.3390/cancers14174186
Cancers, Vol. 14 Núm. 17 (september 2022) , p. 4186
|
|
|
4.
|
|
16 p, 2.1 MB |
Recent therapeutic advances in urothelial carcinoma : A paradigm shift in disease management
/
Bellmunt, J. (Department of Medical Oncology. Beth Israel Deaconess Medical Center and IMIM-PSMAR Lab. Harvard Medical School) ;
Valderrama, B.P. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Puente, J. (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Bolós, M.V. (Pfizer) ;
Laínez, Nuria (Hospital Universitario de Navarra) ;
Vázquez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Climent, Miguel Ángel (Department of Medical Oncology. Valencia Institute of Oncology Foundation) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Arranz, J.Á. (Hospital General Universitario Gregorio Marañón) ;
Durán, Ignacio (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Universitat Autònoma de Barcelona
Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. [...]
2022 - 10.1016/j.critrevonc.2022.103683
Critical Reviews in Oncology/Hematology, Vol. 174 (june 2022) , p. 103683
|
|
|
5.
|
|
14 p, 2.6 MB |
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
/
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Miah, Aisha B. (The Royal Marsden Hospital) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Messiou, Christina (Department of Radiology. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Morosi, Carlo (Radiology Department. Fondazione IRCCS Istituto Nazionale Tumori) ;
Caraceni, Augusto (Fondazione IRCCS Istituto Nazionale Tumori) ;
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center) ;
Bajpai, Jyoti (Homi Bhabha National Institute. Medical Oncology Department) ;
Baldini, Elizabeth Healey (Dana-Farber Cancer Center/Brigham) ;
Bauer, Sebastian (University of Duisburg-Essen) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bielack, Stefan S. (Klinikum Stuttgart - Olgahospital) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Bonvalot, Sylvie (Institut Curie. Department of Surgical Oncology) ;
Boukovinas, Ioannis P. (Nordix) ;
Bovee, Judith V.M.G. (Leiden University Medical Center) ;
Boye, Kjetil (The Norwegian Radium Hospital) ;
Brodowicz, Thomas (Medical University Vienna) ;
Callegaro, Dario (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
De Álava, Enrique (Department of Normal and Pathological Cytology and Histology. School of Medicine. University of Seville) ;
Deoras-Sutliff, M. (The EHE Foundation) ;
Dufresne, Armelle (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Eriksson, Mikael (Department of Oncology. Skane University Hospital and Lund University) ;
Errani, Costantino (Orthopaedic Service. Musculoskeletal Oncology Department. IRCCS Istituto Ortopedico Rizzoli) ;
Fedenko, Alexander (Medical Oncology Division. P.A. Herzen Cancer Research Institute) ;
Ferraresi, Virginia (Sarcomas and Rare Tumors Unit. IRCCS Regina Elena National Cancer Institute) ;
Ferrari, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Fletcher, Christopher D.M. (Department of Pathology Brigham & Women's Hospital) ;
Garcia del Muro, Xavier (Universitat de Barcelona) ;
Gelderblom, Hans J. (Department of Medical Oncology. Leiden University Medical Center) ;
Gladdy, Rebecca A. (University of Toronto and Lunenfeld-Tanenbaum Research Institute) ;
Gouin, François (Department of Surgery. Centre Leon Berard) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Gutkovich, J. (NUY Langone Medical Center) ;
Haas, Rick (Department of Radiotherapy. the Leiden University Medical Center) ;
Hindi, Nadia (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Hohenberger, Peter (Mannheim University Medical Center) ;
Huang, Paul (Division of Molecular Pathology. The Institute of Cancer Research) ;
Joensuu, Heikki T. (Department of Oncology. Helsinki University Hospital & Helsinki University) ;
Jones, Robin Lewis (Department of Cancer. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Jungels, Christiane (Institut Jules Bordet. Université Libre de Bruxelles) ;
Kasper, Bernd (University of Heidelberg. Mannheim University Medical Center. Sarcoma Unit) ;
Kawai, Akira (Musculoskeletal Oncology and Rehabilitation Medicine. Rare Cancer Center National Cancer Center Hospital) ;
Le Cesne, Axel (International Department. Gustave Roussy) ;
Le Grange, Franél (UCLH - University College London Hospitals NHS Foundation Trust) ;
Leithner, Andeas (Department of Orthopaedics and Trauma Medical University Graz) ;
Leonard, H. (Chair of Trustees of the EHE Rare Cancer Charity (UK). Charity number 1162472) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martin Broto, Javier (Hospital Universitario Fundación Jiménez Díaz) ;
Merimsky, Ofer (Unit of Soft Tissue and Bone Oncology. Division of Oncology. Tel-Aviv Medical Center affiliated with Sackler School of Medicine. Tel Aviv University) ;
Merriam, Priscilla (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Mir, Olivier (Sarcoma Group. Gustave Roussy) ;
Molinari, Massimo (University of Pittsburgh Medical Center. Thomas Starzl Transplant Institute) ;
Montemurro, Michael (Oncology. CHUV Lausanne) ;
Oldani, Graziano (Division of Abdominal Surgery. University Hospitals of Geneva) ;
Palmerini, Emanuela (Chemotherapy Unit. IRCCS Istituto Ortopedico Rizzoli) ;
Pantaleo, Maria Abbondanza. (Division of Oncology. IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Patel, Sapna Pradyuman (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Piperno-Neumann, Sophie (Department of Medical Oncology. Institut Curie) ;
Raut, Chandrajit Premanand (Dana Farber Cancer Center. Harvard Medical School) ;
Ravi, Vinod (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Razak, Albiruni Ryan Abdul (Princess Margaret Cancer Centre and Sinai Healthcare System & Faculty of Medicine. University of Toronto) ;
Reichardt, Peter (Helios Klinikum Berlin-Buch. Department of Oncology and Palliative Care) ;
Rubin, Brian P. (Robert J. Tomsich Pathology and Laboratory Medicine Institute. Cleveland Clinic) ;
Rutkowski, Piotr (Maria Sklodowska-Curie National Research Institute of Oncology. Department of Soft Tissue/Bone Sarcoma and Melanoma) ;
Safwat, Akmal Ahmed (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Sapisochin, Gonzalo (Multi-Organ Transplant and HPB Surgical Oncology. Division of General Surgery. Department of Surgery. University of Toronto) ;
Sbaraglia, Marta (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Scheipl, Susanne (Department of Orthopaedics and Trauma. Medical University of Graz) ;
Schöffski, Patrick (Leuven Cancer Institute) ;
Strauss, Dirk Cornelius (Department of Surgery. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Strauss, Sandra J. (University College London Hospital) ;
Sundby Hall, Kirsten (Department of Oncology. Oslo University Hospital. The Norwegian Radium Hospital) ;
Tap, William D. (Department of Medicine. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College) ;
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Tweddle, A. (Palliative Care. The Royal Marsden Hospital and The Institute of Cancer Research London) ;
van der Graaf, Winette T.A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
van de Sande, Michiel (Department of Orthopedic Surgery Bone and Soft Tissue Tumor Unit. Leiden University Medical Center) ;
Van Houdt, Winan (Sarcoma and Melanoma Unit. The Netherlands Cancer Institute) ;
van Oortmerssen, Gerard (Co-Chair of Sarcoma Patients EuroNet (SPAEN). Woelfersheim. Germany & Chairman of the Dutch organisation for sarcoma patients (Patiëntenplatform Sarcomen). Guest researcher at Leiden University (Leiden Institute for Advanced Computer Science). Leiden University) ;
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Wartenberg, Markus (Chair of the Board of Directors of Sarcoma Patients EuroNet (SPAEN). Sarcoma Patients EuroNet (SPAEN)) ;
Wood, J. (The Royal Marsden NHS Foundation Trust) ;
Zaffaroni, Nadia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Zimmermann, Camilla (Department of Supportive Care. Princess Margaret Cancer Centre and Division of Palliative Medicine. Department of Medicine. University of Toronto) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Dei Tos, Angelo (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. [...]
2021 - 10.1016/j.esmoop.2021.100170
ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100170
|
|
|
6.
|
|
10 p, 2.4 MB |
Sarcoma classification by DNA methylation profiling
/
Koelsche, Christian (Heidelberg University Hospital (Alemanya)) ;
Schrimpf, Daniel (German Cancer Research Center) ;
Stichel, Damian (German Cancer Research Center) ;
Sill, Martin (German Cancer Research Center) ;
Sahm, Felix (German Cancer Research Center) ;
Reuss, David E. (German Cancer Research Center) ;
Blattner, Mirjam (German Cancer Research Center) ;
Worst, Barbara (Heidelberg University Hospital (Alemanya)) ;
Heilig, Christoph E. (German Cancer Consortium) ;
Beck, Katja (German Cancer Research Center) ;
Horak, Peter (German Cancer Consortium) ;
Kreutzfeldt, Simon (German Cancer Consortium) ;
Paff, Elke (Heidelberg University Hospital (Alemanya)) ;
Stark, Sebastian (Heidelberg University Hospital (Alemanya)) ;
Johann, Pascal (Heidelberg University Hospital (Alemanya)) ;
Selt, Florian (German Cancer Research Center) ;
Ecker, Jonas (German Cancer Research Center) ;
Sturm, Dominik (Heidelberg University Hospital (Alemanya)) ;
Pajtler, Kristian W. (Heidelberg University Hospital (Alemanya)) ;
Reinhardt, Annekathrin (German Cancer Research Center) ;
Wefers, Annika K. (German Cancer Research Center) ;
Sievers, Philipp (German Cancer Research Center) ;
Ebrahimi, Azadeh (German Cancer Research Center) ;
Suwala, Abigail (German Cancer Research Center) ;
Fernández-Klett, Francisco (German Cancer Research Center) ;
Casalini, Belén (German Cancer Research Center) ;
Korshunov, Andrey (German Cancer Research Center) ;
Hovestadt, Volker (Harvard Medical School) ;
Kommoss, Felix K.F. (DHeidelberg University Hospital) ;
Kriegsmann, Mark (Heidelberg University Hospital (Alemanya)) ;
Schick, Matthias (German Cancer Research Center) ;
Bewerunge-Hudler, Melanie (German Cancer Research Center) ;
Milde, Till (German Cancer Research Center) ;
Witt, Olaf (German Cancer Research Center) ;
Kulozik, Andreas E. (eidelberg University Hospital) ;
Kool, Marcel (German Cancer Research Center) ;
Romero-Pérez, Laura (LMU Munich) ;
Grünewald, Thomas G.P. (LMU Munich) ;
Kirchner, Thomas (LMU Munich) ;
Wick, Wolfgang (German Cancer Research Center) ;
Platten, Michael (German Cancer Research Center) ;
Unterberg, Andreas (Heidelberg University Hospital (Alemanya)) ;
Uhl, Matthias (Heidelberg Institute of Radiation Oncology) ;
Abdollahi, Amir (German Cancer Research Center) ;
Debus, Jürgen (German Cancer Research Center) ;
Lehner, Burkhard (Heidelberg University Hospital (Alemanya)) ;
Thomas, Christian (University Hospital of Münster (Alemanya)) ;
Hasselblatt, Martin (University Hospital of Münster (Alemanya)) ;
Paulus, Werner (University Hospital of Münster (Alemanya)) ;
Hartmann, Christian (Hannover Medical School) ;
Staszewski, Ori (University of Freiburg) ;
Prinz, Marco (University of Freiburg) ;
Hench, Jürgen (University Hospital Basel (Basilea, Suïssa)) ;
Frank, Stephan (University Hospital Basel (Basilea, Suïssa)) ;
Versleijen-Jonkers, Yvonne M.H. (Radboud University Medical Center) ;
Weidema, Marije E. (Radboud University Medical Center) ;
Mentzel, Thomas (Dermatopathology Bodensee) ;
Griewank, Klaus (University Duisburg-Essen) ;
De Álava, Enrique (Universidad de Sevilla) ;
Díaz-Martín, Juan (Instituto de Biomedicina de Sevilla) ;
Idoate Gastearena, Miguel A. (Clínica Universidad de Navarra) ;
Chang, Kenneth Tou-En (Department of Pathology and Laboratory Medicine. KK Women's and Children's Hospital) ;
Low, Sharon Yin Yee (National Neuroscience Institute (Singapur)) ;
Cuevas-Bourdier, Adrian (Laboratoire National de Santé (França)) ;
Mittelbronn, Michel (Luxembourg Institute of Health) ;
Mynarek, Martin (University Medical Center Hamburg-Eppendorf) ;
Rutkowski, Stefan (University Medical Center Hamburg-Eppendorf) ;
Schüller, Ulrich (Research Institute Children's Cancer Center Hamburg) ;
Mautner, Viktor F. (University Medical Center Hamburg-Eppendorf) ;
Schittenhelm, Jens (Institute of Pathology and Neuropathology. University Hospital of Tübingen) ;
Serrano, Jonathan (New York University School of Medicine) ;
Snuderl, Matija (New York University School of Medicine) ;
Büttner, Reinhard (Uniklinik Köln (Colònia, Alemanya)) ;
Klingebiel, Thomas (University Children's Hospital) ;
Buslei, Rolf (Sozialstiftung Bamberg. Klinikum am Bruderwald) ;
Gessler, Manfred (Würzburg University) ;
Wesseling, Pieter (Amsterdam University Medical Centers/VUmc) ;
Dinjens, Winand N.M. (Erasmus MC Cancer Institute) ;
Brandner, Sebastian (University College London Hospitals NHS Foundation Trust) ;
Jaunmuktane, Zane (University College London) ;
Lyskjær, Iben (University College London) ;
Schirmacher, Peter (Heidelberg University Hospital (Alemanya)) ;
Stenzinger, Albretch (Heidelberg University Hospital (Alemanya)) ;
Brors, Benedikt (German Cancer Research Center) ;
Glimm, Hanno (German Cancer Consortium) ;
Heining, Christoph (German Cancer Consortium) ;
Tirado, Oscar M. (Institut d'Investigació Biomèdica de Bellvitge) ;
Sáinz-Jaspeado, Miguel (Institut d'Investigació Biomèdica de Bellvitge) ;
Mora, Jaume (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Alonso, Javier (Instituto de Salud Carlos III) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Moran, S (Institut d'Investigació Biomèdica de Bellvitge) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Benhamida, Jamal K. (Memorial Sloan Kettering Cancer Center) ;
Ladanyi, Marc (Department of Pathology. Memorial Sloan Kettering Cancer Center) ;
Wardelmann, Eva (University Hospital of Münster (Alemanya)) ;
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center) ;
Flanagan, Adrienne (University College London Cancer Institute) ;
Dirksen, Uta (University Duisburg-Essen) ;
Hohenberger, Peter (University of Heidelberg) ;
Baumhoer, Daniel (University Hospital Basel (Basilea, Suïssa)) ;
Hartmann, Wolfgang (University Hospital of Münster (Alemanya)) ;
Vokuhl, Christian (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Flucke, Uta (Radboud University Medical Center) ;
Petersen, Iver (Institute of Pathology) ;
Mechtersheimer, Gunhild (Heidelberg University Hospital (Alemanya)) ;
Capper, David (Charité - Universitätsmedizin Berlin) ;
Jones, David T.W. (PGerman Cancer Research Center) ;
Fröhling, Stefan (German Cancer Consortium) ;
Pfister, Stefan M. (Heidelberg University Hospital (Alemanya)) ;
von Deimling, Andreas (German Cancer Research Center)
Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and children. They represent a morphologically heterogeneous class of tumours and some entities lack defining histopathological features. [...]
2021 - 10.1038/s41467-020-20603-4
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 498
|
|
|
7.
|
|
10 p, 402.2 KB |
SEOM clinical guideline for treatment of kidney cancer (2017)
/
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Méndez-Vidal, M. J. (Instituto Maimónides de Investigación Biomédica de Córdoba) ;
Pérez-Gracia, J. L. (Clínica Universidad de Navarra) ;
Sepúlveda-Sánchez, J. M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Campayo, M. (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Chirivella, Isabel (Hospital Clínic Universitari (València)) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. [...]
2017 - 10.1007/s12094-017-1765-4
Clinical & Translational Oncology, Vol. 20 (november 2017) , p. 47-56
|
|
|
8.
|
|
12 p, 5.3 MB |
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
/
Puente, Javier (Hospital Clínico San Carlos (Madrid)) ;
Laínez, Nuria (Complejo Hospitalario de Navarra) ;
Dueñas, Marta (Centro de Investigación Biomédica en Red de Cáncer) ;
Méndez-Vidal, María José (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Esteban, Emilio (Hospital Universitario Central de Asturias) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Fernández, Mónica (Centro de Investigación Biomédica en Red de Cáncer) ;
Basterretxea, Laura (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Juan-Fita, María José (Instituto Valenciano Oncologia) ;
Antón Aparicio, Luís (Complejo Hospitalario Universitario de A Coruña) ;
Leon-Mateos, Luis (Promoción e Planificación da Investigación Sanitaria, Axencia de Coñecemento en Saúde, Santiago de Compostela, Spain) ;
Lambea, Julio (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Valderrama, Begoña (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Vázquez, Sergio (Hospital Universitario Lucus Augusti (Lugo)) ;
Suárez, Cristina (Universitat Autònoma de Barcelona) ;
Garcia del Muro, Xavier (Institut Català d'Oncologia) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Maroto, José Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Samaniego, M. Luz (TFS HealthScience) ;
Suárez-Paniagua, Beatriz (TFS HealthScience) ;
Sanz, Julián (Hospital Clínico San Carlos (Madrid)) ;
Paramio, Jesús M. (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. [...]
2017 - 10.18632/oncotarget.16494
Oncotarget, Vol. 8 (march 2017) , p. 30410-30421
|
|
|
9.
|
|
20 p, 4.0 MB |
Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine
/
Castellsagué, Joan (Institut Català d'Oncologia) ;
Gel, Bernat (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Fernández-Rodríguez, Juana (Institut Català d'Oncologia) ;
Llatjós, Roger (Institut d'Investigació Biomèdica de Bellvitge) ;
Blanco Guillermo, Ignacio (Institut Català d'Oncologia) ;
Benavente, Yolanda (Institut Català d'Oncologia) ;
Pérez-Sidelnikova, Diana (Institut d'Investigació Biomèdica de Bellvitge) ;
Garcia del Muro, Xavier (Institut Català d'Oncologia) ;
Viñals, Joan Maria (Institut d'Investigació Biomèdica de Bellvitge) ;
Vidal, August (Institut d'Investigació Biomèdica de Bellvitge) ;
Valdés-Mas, Rafael (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ;
Terribas, Ernest (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
López-Doriga, Adriana (Institut Català d'Oncologia) ;
Pujana, Miguel Angel (Institut Català d'Oncologia) ;
Capellá, G. (Gabriel) (Institut Català d'Oncologia) ;
Puente, Xose S. (Instituto Universitario de Oncología del Principado de Asturias (Oviedo)) ;
Serra, Eduard (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ;
Villanueva Garatachea, Alberto (Institut Català d'Oncologia) ;
Lázaro, Conxi (Institut Català d'Oncologia)
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. [...]
2015 - 10.15252/emmm.201404430
EMBO molecular medicine, Vol. 7, No. 5 (2015) , p. 608-627
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
